Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Net Income towards Common Stockholders (2016 - 2025)

Lexaria Bioscience's Net Income towards Common Stockholders history spans 11 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 40.74% year-over-year to $1.6 million; the TTM value through Nov 2025 reached $10.8 million, up 47.95%, while the annual FY2025 figure was $11.9 million, 105.17% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $1.6 million at Lexaria Bioscience, down from $2.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $3.8 million in Q2 2025 and bottomed at -$4.3 million in Q3 2022.
  • The 5-year median for Net Income towards Common Stockholders is $1.4 million (2022), against an average of $729573.8.
  • The largest YoY upside for Net Income towards Common Stockholders was 452.82% in 2022 against a maximum downside of 266.61% in 2022.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$2.0 million in 2021, then skyrocketed by 190.31% to $1.8 million in 2022, then tumbled by 33.33% to $1.2 million in 2023, then surged by 125.0% to $2.7 million in 2024, then tumbled by 40.74% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Net Income towards Common Stockholders are $1.6 million (Q4 2025), $2.7 million (Q3 2025), and $3.8 million (Q2 2025).